Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04528680 | Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma(SC9/ABX) | active not recruiting | Phase 1 / Phase 2 | 57 | Northwestern UniversityOTHER |
| 1 |
| Apr 13, 2026 |
| clinicaltrials |
| NCT05222620 | SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial | recruiting | Phase 2 | 90 | Mayo ClinicOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06159166 | Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).(Mirda) | recruiting | Phase 1 / Phase 2 | 24 | Johns Hopkins UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07505979 | SMART Trial: Cognitive Sparing Brain Radiotherapy for Multiple Brain Metastases | not yet recruiting | Phase 2 | 90 | National Taiwan University HospitalOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 38 | Nationwide Children's HospitalOTHER | 3 | Apr 8, 2026 | clinicaltrials |
| NCT07301268 | GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma | recruiting | Phase 2 | 36 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | recruiting | Phase 2 | 70 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06517888 | Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma | recruiting | Phase 1 / Phase 2 | 27 | Akouos, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511725 | Prophylactic Regimen With Intrathecal Thiotepa in SVZ-positive or Meningeal-risk Glioblastoma(PRISM) | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT07417761 | Tuvusertib in Astrocytoma With ATRX Mutation(TUVASTRAT) | recruiting | Phase 2 | 56 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05267587 | Preop fSRS for Resectable Brain Metastases | active not recruiting | Phase 2 | 49 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05986851 | Azeliragon in MGMT Unmethylated Glioblastoma | active not recruiting | Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03596086 | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | recruiting | Phase 1 / Phase 2 | 62 | David Baskin MDOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03603405 | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | recruiting | Phase 1 / Phase 2 | 62 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04559230 | Sacituzumab Govitecan in Recurrent Glioblastoma | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04947319 | Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) | active not recruiting | Phase 2 | 119 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07502287 | Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma(DUAL-NK-NB) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04801147 | Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme(DENDR1) | completed | Phase 1 / Phase 2 | 76 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT01743950 | A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab | terminated | Phase 2 | 49 | University of Wisconsin, MadisonOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | active not recruiting | Phase 1 / Phase 2 | 24 | Acerta Pharma BVINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04574856 | Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05805631 | Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | recruiting | Phase 2 | 23 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | enrolling by invitation | Phase 1 / Phase 2 | 40 | Xiaorong WuINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04417088 | Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy | completed | Phase 1 / Phase 2 | 28 | InSightecINDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04458272 | A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma | active not recruiting | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT01011920 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | completed | Phase 2 | 227 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 5 | Mar 19, 2026 | clinicaltrials |
| NCT05733572 | Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)(NGF-OPG) | active not recruiting | Phase 2 | 36 | Benedetto FalsiniOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476794 | Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma(TEMPO) | recruiting | Phase 2 | 118 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05753007 | A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients | terminated | Phase 2 | 2 | Mclean HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03475186 | Testing Ramipril to Prevent Memory Loss in People With Glioblastoma | completed | Phase 2 | 75 | Wake Forest University Health SciencesOTHER | 2 | Mar 13, 2026 | clinicaltrials |
| NCT04283669 | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas(NF110) | completed | Phase 2 | 12 | University of Alabama at BirminghamOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05940493 | Abemaciclib in Newly Diagnosed Meningioma Patients | recruiting | Phase 2 | 72 | Nader SanaiOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04044937 | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms(UC-GlioFET) | completed | Phase 2 | 143 | Thomas HopeOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06504381 | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | recruiting | Phase 1 / Phase 2 | 70 | University of California, San FranciscoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05256641 | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05660408 | RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors(RNA PRIME) | active not recruiting | Phase 1 / Phase 2 | 36 | University of FloridaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04197297 | Brain Imaging Biomarkers in Patients With Brain Metastasis | recruiting | Phase 2 | 90 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05681195 | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | recruiting | Phase 2 | 15 | Baptist Health South FloridaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03839498 | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma | active not recruiting | Phase 2 | 6 | Columbia UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03946527 | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)(LAMPARA) | active not recruiting | Phase 2 | 10 | Antonio FojoOTHER | 1 | Mar 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 13, 2026source: clinicaltrials